Skip to main content
Erschienen in: The Cerebellum 6/2015

01.12.2015 | Original Paper

Cerebellar Hypoplasia and Dysmorphia in Neurofibromatosis Type 1

verfasst von: Sandra P. Toelle, Andrea Poretti, Peter Weber, Tatjana Seute, Jacoline E. C. Bromberg, Ianina Scheer, Eugen Boltshauser

Erschienen in: The Cerebellum | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Unidentified bright objects (UBO) and tumors are well-known cerebellar abnormalities in neurofibromatosis type 1 (NF1). Literature reports on malformative cerebellar anomalies in neurofibromatosis type 1 (NF1), however, are scant. We retrospectively studied the clinical and neuroimaging findings of 5 patients with NF1 (4 females, age 6 to 29 years at last follow-up) and cerebellar anomalies. Cerebellar symptoms on neurological examination were mild or even not evident whereas learning disabilities were more or less pronounced in four patients. Two patients had cerebellar hypoplasia (diffusely enlarged cerebellar interfoliar spaces) and three cerebellar dysmorphias involving mainly one cerebellar hemisphere. In NF1, malformative cerebellar anomalies are rare (estimated prevalence of about 1 %), but most likely underestimated and easily overlooked, because physicians tend to focus on more prevalent, obvious, and well-known findings such as optic pathway gliomas, other tumors, and UBO. This kind of cerebellar anomaly in NF1 has most likely a malformative origin, but the exact pathogenesis is unknown. The individual clinical significance is difficult to determine. We suggest that cerebellar anomalies should be systematically evaluated in neuroimaging studies of NF1 patients.
Literatur
1.
Zurück zum Zitat Williams VC, Lucas J, Babcock MA, et al. Neurofibromatosis type 1 revisited. Pediatrics. 2009;123:124–33.CrossRefPubMed Williams VC, Lucas J, Babcock MA, et al. Neurofibromatosis type 1 revisited. Pediatrics. 2009;123:124–33.CrossRefPubMed
2.
Zurück zum Zitat Plotkin SR, Albers AC, Babovic-Vuksanovic D, et al. Update from the 2013 international neurofibromatosis conference. Am J Med Genet A. 2014;164:2969–78.CrossRef Plotkin SR, Albers AC, Babovic-Vuksanovic D, et al. Update from the 2013 international neurofibromatosis conference. Am J Med Genet A. 2014;164:2969–78.CrossRef
3.
Zurück zum Zitat Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13:834–43.CrossRefPubMed Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13:834–43.CrossRefPubMed
4.
Zurück zum Zitat Acosta MT, Gioia GA, Silva AJ. Neurofibromatosis type 1: new insights into neurocognitive issues. Curr Neurol Neurosci Rep. 2006;6:136–43.CrossRefPubMed Acosta MT, Gioia GA, Silva AJ. Neurofibromatosis type 1: new insights into neurocognitive issues. Curr Neurol Neurosci Rep. 2006;6:136–43.CrossRefPubMed
5.
Zurück zum Zitat Acosta MT, Kardel PG, Walsh KS, et al. Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study. Pediatr Neurol. 2011;45:241–5.CrossRefPubMed Acosta MT, Kardel PG, Walsh KS, et al. Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study. Pediatr Neurol. 2011;45:241–5.CrossRefPubMed
6.
Zurück zum Zitat Lidzba K, Granstrom S, Lindenau J, Mautner VF. The adverse influence of attention-deficit disorder with or without hyperactivity on cognition in neurofibromatosis type 1. Dev Med Child Neurol. 2012;54:892–7.CrossRefPubMed Lidzba K, Granstrom S, Lindenau J, Mautner VF. The adverse influence of attention-deficit disorder with or without hyperactivity on cognition in neurofibromatosis type 1. Dev Med Child Neurol. 2012;54:892–7.CrossRefPubMed
7.
Zurück zum Zitat Soucy EA, Gao F, Gutmann DH, Dunn CM. Developmental delays in children with neurofibromatosis type 1. J Child Neurol. 2012;27:641–4.CrossRefPubMed Soucy EA, Gao F, Gutmann DH, Dunn CM. Developmental delays in children with neurofibromatosis type 1. J Child Neurol. 2012;27:641–4.CrossRefPubMed
8.
Zurück zum Zitat Champion JA, Rose KJ, Payne JM, Burns J, North KN. Relationship between cognitive dysfunction, gait, and motor impairment in children and adolescents with neurofibromatosis type 1. Dev Med Child Neurol. 2014;56:468–74.CrossRefPubMed Champion JA, Rose KJ, Payne JM, Burns J, North KN. Relationship between cognitive dysfunction, gait, and motor impairment in children and adolescents with neurofibromatosis type 1. Dev Med Child Neurol. 2014;56:468–74.CrossRefPubMed
9.
Zurück zum Zitat DiMario Jr FJ, Ramsby G. Magnetic resonance imaging lesion analysis in neurofibromatosis type 1. Arch Neurol. 1998;55:500–5.CrossRefPubMed DiMario Jr FJ, Ramsby G. Magnetic resonance imaging lesion analysis in neurofibromatosis type 1. Arch Neurol. 1998;55:500–5.CrossRefPubMed
10.
Zurück zum Zitat Payne JM, Pickering T, Porter M, et al. Longitudinal assessment of cognition and T2-hyperintensities in NF1: an 18-year study. Am J Med Genet A. 2014;164A:661–5.CrossRefPubMed Payne JM, Pickering T, Porter M, et al. Longitudinal assessment of cognition and T2-hyperintensities in NF1: an 18-year study. Am J Med Genet A. 2014;164A:661–5.CrossRefPubMed
11.
Zurück zum Zitat Albers AC, Gutmann DH. Gliomas in patients with neurofibromatosis type 1. Expert Rev Neurother. 2009;9:535–9.CrossRefPubMed Albers AC, Gutmann DH. Gliomas in patients with neurofibromatosis type 1. Expert Rev Neurother. 2009;9:535–9.CrossRefPubMed
12.
Zurück zum Zitat Fisher MJ, Avery RA, Allen JC, et al. Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology. 2013;81:S15–24.PubMedCentralCrossRefPubMed Fisher MJ, Avery RA, Allen JC, et al. Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology. 2013;81:S15–24.PubMedCentralCrossRefPubMed
13.
Zurück zum Zitat Piscitelli O, Digilio MC, Capolino R, Longo D, Di Ciommo V. Neurofibromatosis type 1 and cerebellar T2-hyperintensities: the relationship to cognitive functioning. Dev Med Child Neurol. 2012;54:49–51.CrossRefPubMed Piscitelli O, Digilio MC, Capolino R, Longo D, Di Ciommo V. Neurofibromatosis type 1 and cerebellar T2-hyperintensities: the relationship to cognitive functioning. Dev Med Child Neurol. 2012;54:49–51.CrossRefPubMed
14.
Zurück zum Zitat Pascual-Castroviejo I, Pascual-Pascual SI, Viano J, et al. Posterior fossa tumors in children with neurofibromatosis type 1 (NF1). Childs Nerv Syst. 2010;26:1599–603.CrossRefPubMed Pascual-Castroviejo I, Pascual-Pascual SI, Viano J, et al. Posterior fossa tumors in children with neurofibromatosis type 1 (NF1). Childs Nerv Syst. 2010;26:1599–603.CrossRefPubMed
15.
Zurück zum Zitat Riccardi VM. Neurofibromatosis. Baltimore: The Johns Hopkins University Press; 1992. p. 63. Riccardi VM. Neurofibromatosis. Baltimore: The Johns Hopkins University Press; 1992. p. 63.
16.
Zurück zum Zitat Poretti A, Boltshauser E, Doherty D. Cerebellar hypoplasia: differential diagnosis and diagnostic approach. Am J Med Genet C: Semin Med Genet. 2014;166C:211–26.CrossRef Poretti A, Boltshauser E, Doherty D. Cerebellar hypoplasia: differential diagnosis and diagnostic approach. Am J Med Genet C: Semin Med Genet. 2014;166C:211–26.CrossRef
17.
Zurück zum Zitat Poretti A, Wolf NI, Boltshauser E. Differential diagnosis of cerebellar atrophy in childhood. Eur J Paediatr Neurol. 2008;12:155–67.CrossRefPubMed Poretti A, Wolf NI, Boltshauser E. Differential diagnosis of cerebellar atrophy in childhood. Eur J Paediatr Neurol. 2008;12:155–67.CrossRefPubMed
18.
Zurück zum Zitat Poretti A, Boltshauser E. Cerebellar dysplasia. In: Boltshauser E, Schmahmann JD, editors. Cerebellar disorders in children. London: Mac Keith Press; 2012. p. 172–6. Poretti A, Boltshauser E. Cerebellar dysplasia. In: Boltshauser E, Schmahmann JD, editors. Cerebellar disorders in children. London: Mac Keith Press; 2012. p. 172–6.
19.
Zurück zum Zitat Isikay S. Cerebellar hypoplasia in a case with neurofibromatosis type 1. BMJ Case Rep 2013;2013. Isikay S. Cerebellar hypoplasia in a case with neurofibromatosis type 1. BMJ Case Rep 2013;2013.
20.
Zurück zum Zitat Ruggieri M, Upadhyaya M, Di Rocco C, Gabriele A, Pascual-Castroviejo I. Neurofibromatosis type 1 & related disorders. In: Ruggieri M, Pascual-Castroviejo I, Di Rocco C, editors. Neurocutaneous disorders. New York: Springer; 2008. p. 51–151. Ruggieri M, Upadhyaya M, Di Rocco C, Gabriele A, Pascual-Castroviejo I. Neurofibromatosis type 1 & related disorders. In: Ruggieri M, Pascual-Castroviejo I, Di Rocco C, editors. Neurocutaneous disorders. New York: Springer; 2008. p. 51–151.
21.
Zurück zum Zitat Pascual-Castroviejo I, Pascual-Pascual SI, Burgueno M, et al. [Unilateral facial and cerebral hyperplasia associated with neurofibromatosis type 1. Report of four patients]. Rev Neurol. 2006;43:346–52.PubMed Pascual-Castroviejo I, Pascual-Pascual SI, Burgueno M, et al. [Unilateral facial and cerebral hyperplasia associated with neurofibromatosis type 1. Report of four patients]. Rev Neurol. 2006;43:346–52.PubMed
22.
Zurück zum Zitat Al-Hail H, Ruiz-Miyares F, Deleu D, Mesraoua B. [Cerebellar hypoplasia and vertebral indentations in a case of neurofibromatosis type I]. Rev Neurol. 2008;46:626–7.PubMed Al-Hail H, Ruiz-Miyares F, Deleu D, Mesraoua B. [Cerebellar hypoplasia and vertebral indentations in a case of neurofibromatosis type I]. Rev Neurol. 2008;46:626–7.PubMed
23.
Zurück zum Zitat Rea D, Brandsema JF, Armstrong D, et al. Cerebral arteriopathy in children with neurofibromatosis type 1. Pediatrics. 2009;124:e476–83.CrossRefPubMed Rea D, Brandsema JF, Armstrong D, et al. Cerebral arteriopathy in children with neurofibromatosis type 1. Pediatrics. 2009;124:e476–83.CrossRefPubMed
24.
Zurück zum Zitat Ghosh PS, Rothner AD, Emch TM, Friedman NR, Moodley M. Cerebral vasculopathy in children with neurofibromatosis type 1. J Child Neurol. 2013;28:95–101.CrossRefPubMed Ghosh PS, Rothner AD, Emch TM, Friedman NR, Moodley M. Cerebral vasculopathy in children with neurofibromatosis type 1. J Child Neurol. 2013;28:95–101.CrossRefPubMed
25.
Zurück zum Zitat Kaas B, Huisman TA, Tekes A, et al. Spectrum and prevalence of vasculopathy in pediatric neurofibromatosis type 1. J Child Neurol. 2013;28:561–9.PubMedCentralCrossRefPubMed Kaas B, Huisman TA, Tekes A, et al. Spectrum and prevalence of vasculopathy in pediatric neurofibromatosis type 1. J Child Neurol. 2013;28:561–9.PubMedCentralCrossRefPubMed
26.
Zurück zum Zitat Sanchez-Ortiz E, Cho W, Nazarenko I, et al. NF1 regulation of RAS/ERK signaling is required for appropriate granule neuron progenitor expansion and migration in cerebellar development. Genes Dev. 2014;28:2407–20.PubMedCentralCrossRefPubMed Sanchez-Ortiz E, Cho W, Nazarenko I, et al. NF1 regulation of RAS/ERK signaling is required for appropriate granule neuron progenitor expansion and migration in cerebellar development. Genes Dev. 2014;28:2407–20.PubMedCentralCrossRefPubMed
27.
Zurück zum Zitat Benbir G, Kara S, Yalcinkaya BC, et al. Unilateral cerebellar hypoplasia with different clinical features. Cerebellum. 2011;10:49–60.CrossRefPubMed Benbir G, Kara S, Yalcinkaya BC, et al. Unilateral cerebellar hypoplasia with different clinical features. Cerebellum. 2011;10:49–60.CrossRefPubMed
28.
Zurück zum Zitat Poretti A, Prayer D, Boltshauser E. Morphological spectrum of prenatal cerebellar disruptions. Eur J Paediatr Neurol. 2009;13:397–407.CrossRefPubMed Poretti A, Prayer D, Boltshauser E. Morphological spectrum of prenatal cerebellar disruptions. Eur J Paediatr Neurol. 2009;13:397–407.CrossRefPubMed
29.
Zurück zum Zitat Poretti A, Limperopoulos C, Roulet-Perez E, et al. Outcome of severe unilateral cerebellar hypoplasia. Dev Med Child Neurol. 2010;52:718–24.CrossRefPubMed Poretti A, Limperopoulos C, Roulet-Perez E, et al. Outcome of severe unilateral cerebellar hypoplasia. Dev Med Child Neurol. 2010;52:718–24.CrossRefPubMed
30.
Zurück zum Zitat Massoud M, Cagneaux M, Garel C, et al. Prenatal unilateral cerebellar hypoplasia in a series of 26 cases: significance and implications for prenatal diagnosis. Ultrasound Obstet Gynecol. 2014;44:447–54.CrossRefPubMed Massoud M, Cagneaux M, Garel C, et al. Prenatal unilateral cerebellar hypoplasia in a series of 26 cases: significance and implications for prenatal diagnosis. Ultrasound Obstet Gynecol. 2014;44:447–54.CrossRefPubMed
31.
Zurück zum Zitat Gutmann DH, Rasmussen SA, Wolkenstein P, et al. Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology. 2002;59:759–61.CrossRefPubMed Gutmann DH, Rasmussen SA, Wolkenstein P, et al. Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology. 2002;59:759–61.CrossRefPubMed
32.
Zurück zum Zitat Huttner AJ, Kieran MW, Yao X, et al. Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatr Blood Cancer. 2010;54:890–6.PubMed Huttner AJ, Kieran MW, Yao X, et al. Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatr Blood Cancer. 2010;54:890–6.PubMed
33.
Zurück zum Zitat Jeong TS, Yee GT. Glioblastoma in a patient with neurofibromatosis type 1: a case report and review of the literature. Brain Tumor Res Treat. 2014;2:36–8.PubMedCentralCrossRefPubMed Jeong TS, Yee GT. Glioblastoma in a patient with neurofibromatosis type 1: a case report and review of the literature. Brain Tumor Res Treat. 2014;2:36–8.PubMedCentralCrossRefPubMed
34.
Zurück zum Zitat Weingart MF, Roth JJ, Hutt-Cabezas M, et al. Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target. Oncotarget 2014. Weingart MF, Roth JJ, Hutt-Cabezas M, et al. Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target. Oncotarget 2014.
35.
Zurück zum Zitat Wassmer E, Davies P, Whitehouse WP, Green SH. Clinical spectrum associated with cerebellar hypoplasia. Pediatr Neurol. 2003;28:347–51.CrossRefPubMed Wassmer E, Davies P, Whitehouse WP, Green SH. Clinical spectrum associated with cerebellar hypoplasia. Pediatr Neurol. 2003;28:347–51.CrossRefPubMed
36.
Zurück zum Zitat North K, Hyman S, Barton B. Cognitive deficits in neurofibromatosis 1. J Child Neurol. 2002;17:605–12. discussion 27–9, 46–51.CrossRefPubMed North K, Hyman S, Barton B. Cognitive deficits in neurofibromatosis 1. J Child Neurol. 2002;17:605–12. discussion 27–9, 46–51.CrossRefPubMed
37.
Zurück zum Zitat Hyman SL, Arthur Shores E, North KN. Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. Dev Med Child Neurol. 2006;48:973–7.CrossRefPubMed Hyman SL, Arthur Shores E, North KN. Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. Dev Med Child Neurol. 2006;48:973–7.CrossRefPubMed
38.
Zurück zum Zitat Lorenzo J, Barton B, Acosta MT, North K. Mental, motor, and language development of toddlers with neurofibromatosis type 1. J Pediatr. 2011;158:660–5.CrossRefPubMed Lorenzo J, Barton B, Acosta MT, North K. Mental, motor, and language development of toddlers with neurofibromatosis type 1. J Pediatr. 2011;158:660–5.CrossRefPubMed
Metadaten
Titel
Cerebellar Hypoplasia and Dysmorphia in Neurofibromatosis Type 1
verfasst von
Sandra P. Toelle
Andrea Poretti
Peter Weber
Tatjana Seute
Jacoline E. C. Bromberg
Ianina Scheer
Eugen Boltshauser
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
The Cerebellum / Ausgabe 6/2015
Print ISSN: 1473-4222
Elektronische ISSN: 1473-4230
DOI
https://doi.org/10.1007/s12311-015-0658-8

Weitere Artikel der Ausgabe 6/2015

The Cerebellum 6/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.